H. Gray

发表

Common polymorphisms in TP53 and MDM2 and the relationship to TP53 mutations and clinical outcomes in women with ovarian and peritoneal carcinomas

Rochelle L. Garcia, E. Swisher, V. Galic, 2007, Genes, chromosomes & cancer.

Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer.

George Coukos, Michael N Liebman, Marco Massobrio, 2003, The New England journal of medicine.

Epithelial ovarian cancer.

Ardeshir Hakam, Paul Sabbatini, P. Grigsby, 2011, Journal of the National Comprehensive Cancer Network : JNCCN.

Epithelial Ovarian CancerPractice Guidelines in Oncology

P. Grigsby, R. Burger, P. Sabbatini, 2011 .

Phase I combination study of the PARP inhibitor veliparib plus carboplatin and gemcitabine in patients with advanced ovarian cancer and other solid malignancies.

H. Gray, G. Fleming, Lainie P. Martin, 2018, Gynecologic oncology.

Ovarian cancer, version 3.2012.

R. Burger, M. Dwyer, P. Sabbatini, 2012, Journal of the National Comprehensive Cancer Network : JNCCN.

Recurrence patterns after extended treatment with bevacizumab for ovarian, fallopian tube, and primary peritoneal cancers.

B. Goff, H. Gray, M. D. Dao, 2013, Gynecologic oncology.

Route of hysterectomy and surgical outcomes from a statewide gynecologic oncology population: is there a role for vaginal hysterectomy?

B. Goff, H. Gray, C. Morse, 2016, American journal of obstetrics and gynecology.

Pelvic exenteration in the age of modern chemoradiation.

B. Goff, H. Gray, Weiya Zhang, 2011, Gynecologic oncology.

Ovarian cancer, version 1.2016: Clinical practice guidelines in oncology

P. Sabbatini, E. Ratner, L. Havrilesky, 2016 .

NCCN CLINICAL PRACTICE GUIDELINES IN ONCOLOGY Ovarian Cancer, Version 2.2020

Malley, D. Matei, A. Berchuck, 2021 .

OVARIO phase II trial of combination niraparib plus bevacizumab maintenance therapy in advanced ovarian cancer following first-line platinum-based chemotherapy with bevacizumab.

Richard G. Moore, H. Gray, G. Konecny, 2022, Gynecologic oncology.

Ovarian cancer in the elderly: outcomes with neoadjuvant chemotherapy or primary cytoreduction.

B. Goff, H. Gray, K. McLean, 2008, Gynecologic oncology.

Ovarian Cancer Chemotherapy

H. Gray, 2016 .

Intratumoral T cells and survival in epithelial ovarian cancer

Lin Zhang, P. Gimotty, D. Katsaros, 2003 .

Diffusion of Intraperitoneal Chemotherapy in Women with Advanced Ovarian Cancer in Community Settings 2003–2008: The Effect of the NCI Clinical Recommendation

H. Gray, M. O'Keeffe-Rosetti, A. Bogart, 2014, Front. Oncol..

Combining a symptom index, CA125 and HE4 (triple screen) to detect ovarian cancer in women with a pelvic mass.

M. Neradilek, B. Goff, H. Gray, 2017, Gynecologic oncology.

Antibody immunity to the p53 oncogenic protein is a prognostic indicator in ovarian cancer.

N. Urban, M. McIntosh, C. Drescher, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Patterns and duration of primary and recurrent treatment in ovarian cancer patients with germline BRCA mutations

Rochelle L. Garcia, E. Swisher, H. Gray, 2019, Gynecologic oncology reports.

Surgery for ovarian cancer: rationale and guidelines.

H. Gray, R. Swensen, B. Greer, 2004, Journal of the National Comprehensive Cancer Network : JNCCN.

FOXP3+ regulatory T-cells are abundant in vulvar Paget's disease and are associated with recurrence.

Rochelle L. Garcia, K. Allison, B. Goff, 2011, Gynecologic oncology.

Common polymorphism in interleukin 6 influences survival of women with ovarian and peritoneal carcinoma.

Rochelle L. Garcia, E. Swisher, V. Galic, 2006, Gynecologic oncology.

Ovarian Cancer, Version 1.2016, NCCN Clinical Practice Guidelines in Oncology.

P. Sabbatini, E. Ratner, L. Havrilesky, 2016, Journal of the National Comprehensive Cancer Network : JNCCN.

Intraperitoneal ports placed at the time of bowel resection for treatment of ovarian cancer: Complications and surgical outcomes.

H. Gray, R. Urban, A. Kay, 2019, Gynecologic oncology.

Supplemental online content for : NCCN Guidelines ® Insights : Ovarian Cancer , Version 1 . 2019

D. Matei, A. Berchuck, J. Berek, 2019 .

Combined weekly topotecan and biweekly bevacizumab in women with platinum‐resistant ovarian, peritoneal, or fallopian tube cancer

B. Goff, H. Gray, P. Paley, 2011, Cancer.

Lapatinib and potential prognostic value of EGFR mutations in a Gynecologic Oncology Group phase II trial of persistent or recurrent endometrial cancer.

Andrew K Godwin, A. Godwin, K. Leslie, 2012, Gynecologic oncology.

Correlation of imaging and plasma based biomarkers to predict response to bevacizumab in epithelial ovarian cancer (EOC).

Danielle M. Enserro, R. Burger, Hong Liu, 2021, Gynecologic oncology.

NCCN Guidelines® Insights: Ovarian Cancer, Version 3.2022.

D. Matei, A. Berchuck, M. Dwyer, 2022, Journal of the National Comprehensive Cancer Network : JNCCN.

Prognostic and predictive blood-based biomarkers (BMs) in patients (pts) with advanced epithelial ovarian cancer (EOC) treated with carboplatin–paclitaxel (CP) ± bevacizumab (BEV): Results from GOG-0218.

R. Burger, M. Birrer, A. Secord, 2016 .

Ovarian cancer, version 2.2013.

R. Burger, M. Dwyer, P. Sabbatini, 2013, Journal of the National Comprehensive Cancer Network : JNCCN.

Glassy cell carcinoma of the cervix revisited.

Rochelle L. Garcia, B. Goff, H. Gray, 2002, Gynecologic oncology.

We need a new paradigm in gynecologic cancer care: SGO proposes solutions for delivery, quality and reimbursement policies.

W. Cliby, M. Spillman, L. Havrilesky, 2013, Gynecologic oncology.

Progression-free and overall survival in ovarian cancer patients treated with CVac, a mucin 1 dendritic cell therapy in a randomized phase 2 trial

H. Kohrt, J. Berek, A. Secord, 2016, Journal of Immunotherapy for Cancer.

Tackling the opioid crisis: Reduced postoperative oral and intravenous opioid use after implementation of an enhanced recovery after surgery (ERAS) program in gynecologic oncology patients

B. Goff, H. Gray, K. Pennington, 2018, Gynecologic Oncology.

The optimal management of brain metastases from gestational trophoblastic neoplasia

N. Mayr, S. Lo, A. Sahgal, 2022, Expert review of anticancer therapy.

Postoperative narcotic use in patients with ovarian cancer on an Enhanced Recovery After Surgery (ERAS) pathway.

B. Goff, H. Gray, M. Venn, 2019, Gynecologic oncology.

Delayed Hemorrhage After Cervical Conization Unmasking Severe Factor XI Deficiency

S. Rubin, H. Gray, S. Srinivas, 2004, Obstetrics and Gynecology.

Heterotopic atypical trophoblasts mimicking ectopic choriocarcinoma coexistent with a viable intrauterine pregnancy: A diagnostic dilemma

H. Gray, C. Morse, V. Mazina, 2019, Gynecologic oncology reports.

Alisertib in Combination With Weekly Paclitaxel in Patients With Advanced Breast Cancer or Recurrent Ovarian Cancer: A Randomized Clinical Trial

K. Venkatakrishnan, R. Kurzrock, I. Ray-Coquard, 2019, JAMA oncology.

Association of MGMT Promoter Methylation Status With Survival Outcomes in Patients With High-Risk Glioma Treated With Radiotherapy and Temozolomide: An Analysis From the NRG Oncology/RTOG 0424 Trial

K. Aldape, M. Mehta, B. Fisher, 2018, JAMA oncology.

The association between HIV infection and cervical cancer presentation and survival in Uganda☆

S. Schwartz, H. Gray, E. Krantz, 2019, Gynecologic Oncology Reports.

Ovarian Cancer, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology.

D. Matei, A. Berchuck, E. Ratner, 2021, Journal of the National Comprehensive Cancer Network : JNCCN.

Phase II trial of bevacizumab in the treatment of persistent or recurrent squamous cell carcinoma of the cervix: a gynecologic oncology group study.

B. Monk, R. Burger, H. Gray, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase I study of intravenous or intraperitoneal platinum based chemotherapy in combination with veliparib and bevacizumab in newly diagnosed ovarian, primary peritoneal and fallopian tube cancer.

A. Chen, P. Fracasso, H. Gray, 2019, Gynecologic oncology.

Predictive Blood-Based Biomarkers in Patients with Epithelial Ovarian Cancer Treated with Carboplatin and Paclitaxel with or without Bevacizumab: Results from GOG-0218

R. Burger, K. Owzar, M. Birrer, 2020, Clinical Cancer Research.

Intratumoral T cells, tumor-associated macrophages, and regulatory T cells: association with p53 mutations, circulating tumor DNA and survival in women with ovarian cancer.

Rochelle L. Garcia, E. Swisher, K. Allison, 2008, Gynecologic oncology.

Ovarian cancer, version 2.2013: Featured updates to the NCCN guidelines

R. Burger, M. Dwyer, P. Sabbatini, 2013 .

Saphenous vein sparing during inguinal lymphadenectomy to reduce morbidity in patients with vulvar carcinoma.

M. Morgan, S. Rubin, H. Gray, 2006, Gynecologic oncology.

A Phase I-II Evaluation of Veliparib (NSC #737664), Topotecan, and Filgrastim or Pegfilgrastim in the Treatment of Persistent or Recurrent Carcinoma of the Uterine Cervix: An NRG Oncology/Gynecologic Oncology Group Study

D. Dawson, J. Lea, H. Gray, 2014, International Journal of Gynecologic Cancer.

Phase I study of ABT-888 in combination with carboplatin and gemcitabine in subjects with advanced solid tumors.

V. Giranda, H. Gray, G. Fleming, 2013 .

Randomized Trial of Intravenous Versus Intraperitoneal Chemotherapy Plus Bevacizumab in Advanced Ovarian Carcinoma: An NRG Oncology/Gynecologic Oncology Group Study.

D. Alberts, S. Rubin, H. Gray, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Paclitaxel With and Without Pazopanib for Persistent or Recurrent Ovarian Cancer: A Randomized Clinical Trial

A. Sood, Wei Hu, H. Gray, 2017, JAMA oncology.

RADIATION THERAPY ONCOLOGY GROUP RTOG 0724 PHASE III RANDOMIZED STUDY OF CONCURRENT CHEMOTHERAPY AND PELVIC RADIATION THERAPY WITH OR WITHOUT ADJUVANT CHEMOTHERAPY IN HIGH-RISK PATIENTS WITH EARLY-STAGE CERVICAL CARCINOMA FOLLOWING RADICAL HYSTERECTOMY

M. Salehpour, H. Gray, M. Wilmoth, 2009 .

Society of Gynecologic Oncology (SGO) 2021 meeting report: Scaling new heights with innovative cancer care.

A. Secord, H. Gray, 2021, Gynecologic Oncology.

Trends in treatment of advanced epithelial ovarian cancer in the Medicare population.

D. Flum, N. Weiss, B. Goff, 2011, Gynecologic oncology.

A phase II evaluation of cediranib in the treatment of recurrent or persistent endometrial cancer: An NRG Oncology/Gynecologic Oncology Group study.

K. Leslie, H. Gray, J. Schilder, 2015, Gynecologic oncology.

Phase II OVARIO study of niraparib + bevacizumab therapy in advanced ovarian cancer following front-line platinum-based chemotherapy with bevacizumab

Richard O. Moore, H. Gray, G. Konecny, 2020, Gynecologic Oncology.

Study of autologous dendritic cell therapy targeting Mucin 1 as a treatment for the maintenance of ovarian cancer patients in remission

J. Berek, A. Secord, H. Gray, 2013, Journal of Immunotherapy for Cancer.

Timing and duration of bevacizumab treatment and survival in patients with recurrent ovarian, fallopian tube, and peritoneal cancer: a multi-institution study

James Y. Dai, B. Goff, H. Gray, 2023, European journal of gynaecological oncology.

Phase II evaluation of dalantercept in the treatment of persistent or recurrent epithelial ovarian cancer: An NRG Oncology/Gynecologic Oncology Group study.

R. Burger, H. Gray, C. Aghajanian, 2018, Gynecologic oncology.

Primary management of early stage cervical cancer (IA1-IB) and appropriate selection of adjuvant therapy.

H. Gray, Heidi J Gray, 2008, Journal of the National Comprehensive Cancer Network : JNCCN.

Alternative intraperitoneal chemotherapy regimens for optimally debulked ovarian cancer.

B. Goff, H. Gray, C. Shah, 2010, Gynecologic oncology.

A study of autologous dendritic cell therapy targeting mucin-1 for treatment of patients with epithelial ovarian cancer in first remission.

J. Berek, H. Gray, J. Fiorica, 2012 .

prognostic value of EGFR mutations in a Gynecologic Oncology Group phase II trial of persistent or recurrent endometrial cancer

A. Godwin, H. Gray, H. Lankes, 2012 .

Revisiting Minimally Invasive Surgery in the Management of Early-Stage Cervical Cancer.

H. Gray, K. Pennington, R. Urban, 2019, Journal of the National Comprehensive Cancer Network : JNCCN.

Advances in vulvar and vaginal cancer treatment.

H. Gray, 2010, Gynecologic oncology.

Ovarian cancer outcomes: Predictors of early death.

B. Goff, H. Gray, R. Urban, 2016, Gynecologic oncology.

Quality of Life and Adverse Events: Prognostic Relationships in Long-Term Ovarian Cancer Survival.

B. Monk, R. Burger, K. Nephew, 2021, Journal of the National Cancer Institute.

Uterine Lavage Identifies Cancer Mutations and Increased TP53 Somatic Mutation Burden in Individuals with Ovarian Cancer

Brendan F. Kohrn, E. Swisher, R. Katz, 2022, Cancer research communications.

Measurements of adiposity as prognostic biomarkers for survival with anti-angiogenic treatment in epithelial ovarian cancer: An NRG Oncology/Gynecologic Oncology Group ancillary data analysis of GOG 218.

Y. Wang, R. Burger, H. Gray, 2019, Gynecologic oncology.

Participation of Patients With Limited English Proficiency in Gynecologic Oncology Clinical Trials.

E. Swisher, H. Gray, K. Doll, 2023, Journal of the National Comprehensive Cancer Network : JNCCN.

Thirty-Day Mortality After Primary Cytoreductive Surgery for Advanced Ovarian Cancer in the Elderly

D. Flum, B. Goff, H. Gray, 2011, Obstetrics and gynecology.

Neoadjuvant chemotherapy in the Medicare cohort with advanced ovarian cancer.

D. Flum, N. Weiss, B. Goff, 2011, Gynecologic oncology.

Extraordinary clinical response to ibrutinib in low-grade ovarian cancer guided by organoid drug testing

Hallie A. Swan, Robert L. Diaz, Shalini C. Pereira, 2023, NPJ precision oncology.

Post hoc analyses of GOG 9923: Does BRCA status affect toxicities?: An NRG oncology study.

A. Chen, P. Fracasso, H. Gray, 2021, Gynecologic oncology.

Neoplastic cellularity is associated with clinical and molecular features of high-grade serous ovarian carcinoma.

Rochelle L. Garcia, E. Swisher, B. Goff, 2015, Gynecologic oncology.

Carboplatin dosing in the treatment of ovarian cancer: An NRG oncology group study.

R. Wenham, A. Secord, P. Sabbatini, 2023, Gynecologic oncology.

An evaluation of cervical cancer in women age sixty and over.

Rochelle L. Garcia, E. Swisher, B. Goff, 2008, Gynecologic oncology.

P1-13-04: Phase II Study of Topical Imiquimod and Abraxane for Treatment of Breast Cancer Cutaneous Metastases.

H. Gray, Hailing Lu, M. Disis, 2011 .

Characterization of the Early Years of Bevacizumab Use for First-Line Treatment of Ovarian Cancer in the United States

D. Enquobahrie, B. Goff, H. Gray, 2021, JCO oncology practice.

Phase II prospective study of weekly topotecan and bevacizumab in platinum refractory ovarian cancer or peritoneal cancer (OC)

H. Gray, P. Paley, H. Muntz, 2008 .

Phase I/II study of weekly paclitaxel with or without MLN8237 (alisertib), an investigational aurora A kinase inhibitor, in patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer (OC), or breast cancer (BrC): Phase I results.

R. Kurzrock, B. Goff, H. Gray, 2012 .

A phase I study of veliparib incorporated into front-line platinum based cheotherpy and bevacizumab in epithelial ovarian cancer (NCT00989651): A GOG/nrg trial.

A. Chen, P. Fracasso, H. Gray, 2019, Journal of Clinical Oncology.

Progression-free survival in ovarian cancer patients in second remission with mucin-1 autologous dendritic cell therapy.

H. Gray, S. Gargosky, C. Team, 2014 .

Painful clitoromegaly caused by rare epithelioid hemangioma.

M. Rendi, H. Gray, M. Holmes, 2013, Gynecologic oncology case reports.

Randomized Trial of Intravenous Versus Intraperitoneal Chemotherapy Plus Bevacizumab in Advanced Ovarian Carcinoma: An NRG Oncology/Gynecologic Oncology Group Study.

D. Alberts, S. Rubin, H. Gray, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II trial of bevacizumab in the treatment of persistent or recurrent squamous cell carcinoma of the cervix: a gynecologic oncology group study.

B. Monk, R. Burger, H. Gray, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The Abandoned Radical Hysterectomy for Cervical Cancer: Clinical Predictors and Outcomes

B. Goff, H. Gray, W. Koh, 2010, Obstetrics and gynecology international.

Neoadjuvant chemotherapy in the Medicare cohort with advanced ovarian cancer.

D. Flum, N. Weiss, B. Goff, 2011, Gynecologic oncology.

Ovarian cancer outcomes: Predictors of early death.

B. Goff, H. Gray, R. Urban, 2016, Gynecologic oncology.

NCCN Guidelines Insights: Ovarian Cancer, Version 1.2019.

D. Matei, A. Berchuck, J. Berek, 2019, Journal of the National Comprehensive Cancer Network : JNCCN.

Phase I combination study of the PARP inhibitor veliparib plus carboplatin and gemcitabine in patients with advanced ovarian cancer and other solid malignancies.

H. Gray, G. Fleming, W. Munasinghe, 2018, Gynecologic Oncology.